Tango Therapeutics Inc (NASDAQ:TNGX)’s traded shares stood at 1.52 million during the last session, with the company’s beta value hitting 0.75. At the close of trading, the stock’s price was $3.47, to imply a decrease of -1.42% or -$0.05 in intraday trading. The TNGX share’s 52-week high remains $13.01, putting it -274.93% down since that peak but still an impressive 22.19% since price per share fell to its 52-week low of $2.70. The company has a valuation of $372.74M, with an average of 1.33 million shares in intraday trading volume over the past 10 days and average of 1.89 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Tango Therapeutics Inc (TNGX), translating to a mean rating of 1.11. Of 3 analyst(s) looking at the stock, 0 analyst(s) give TNGX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.34.
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
After registering a -1.42% downside in the last session, Tango Therapeutics Inc (TNGX) has traded red over the past five days. The 5-day price performance for the stock is -14.95%, and -33.01% over 30 days. With these gigs, the year-to-date price performance is -64.95%. Short interest in Tango Therapeutics Inc (NASDAQ:TNGX) saw shorts transact 7.11 million shares and set a 2.43 days time to cover.
The extremes give us $13 and $18 for target low and target high price respectively. As such, TNGX has been trading -418.73% off suggested target high and -274.64% from its likely low.
Tango Therapeutics Inc (TNGX) estimates and forecasts
Looking at statistics comparing Tango Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Tango Therapeutics Inc (TNGX) shares are -51.81% down over the last 6 months, with its year-to-date growth rate lower than industry average at -10.19% against 17.40%. The rating firms project that company’s revenue will grow 25.91% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 8.02M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 7.37M.Earnings reports from the last fiscal year show that sales brought in 5.43M and 6.47M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 47.64% before jumping 13.89% in the following quarter.
TNGX Dividends
Tango Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders
Tango Therapeutics Inc insiders hold 12.84% of total outstanding shares, with institutional holders owning 100.69% of the shares at 115.52% float percentage. In total, 100.69% institutions holds shares in the company, led by TRV GP IV, LLC. As of 2024-06-30, the company held over 19.2 million shares (or 17.751% of shares), all amounting to roughly $164.75 million.
The next major institution holding the largest number of shares is ECOR1 CAPITAL, LLC with 13.33 million shares, or about 12.3237% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $114.38 million.
